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Abstract
Background: The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with
osteosarcoma registered within the French Sarcoma Group – Bone Tumor Study Group (GSF-GETO) national
registry.
Methods: All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed.
Results: Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The
median age at the beginning of treatment was 19 years (range 9–72). The median number of previous lines of
chemotherapy was 3 (range 1–8). Before inclusion, 3 patients were in second complete remission, 26 were in
progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with
cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5 % of
patients (95 % Confidence Interval (CI) [20–52.8]). The median Progression-Free Survival (PFS) was 3 months (95 %
CI [2–5.4]) for patients treated by sirolimus and 1.8 months (95 % CI [1.3–2.8]) for patients receiving multi-targeted
tyrosine kinase inhibitors; 6-month PFS 15 %. The median Overall Survival (OS) was 6.8 months (95 % CI [4.7–12.1]),
and one-year OS was 24 %. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to
other TTs (Hazard Ratio (HR) = 2.7, 95 % CI [1.05–7.1]). No toxic death was reported. Grade 3 and 4 toxicities were
observed in 27 and 6 % of cases respectively.
Conclusion: Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with
an acceptable toxicity profile, including in pediatric population.
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Background
High-grade osteosarcoma is the most common malig-
nant bone tumor in adolescents and young adults [1].
Multimodal treatment including chemotherapy and rad-
ical surgery increased the Progression-Free-Survival
(PFS) from 10 to 65 % [2]. However, we still observe
30 % of relapse, mainly with metastatic stage, with less
than 20 % long-term survival for these patients [3].
The role of chemotherapy in recurrent osteosarcomas is
not fully established [4]. There is no standard regimen
recommended for second-line treatment [1, 5]. Except for
muramyl tripeptide (L-MTP-PE) which demonstrated an
improvement of median time to relapse from 4,5 months
to 9 months in a phase II trial [6], recently tested drugs
(etoposide, carboplatine, gemcitabine, high dose chemo-
therapy [7], ecteinascidin [8], samarium [9]) failed to im-
prove long-term survival of these patients [10, 11].
Several biological pathways are implicated in bone
sarcomas and represent a potential interesting approach
for the treatment of such tumors with targeted therapies
(TTs) : sustaining proliferative signal (IGFR, SHH/GLI,
PDGFR, c-KIT), evading cell growth suppressors (p53, RB,
CDK), resisting to cell death (ERK activation, proapoptotic
molecule inhibition, antiapoptotic molecule activation
Bcl2, syndecan-2), enabling replicative immortality, in-
creasing angiogenesis (VEGFR, IGFR, PDGFR, HIF1α)
and activating invasion and metastasis, genome instability
(p53, GADD45), evading immune destruction (IFN), or
interacting with the bone microenvironment (RANK/
RANKL/OPG) [12]. Unfortunately, the rarity of these
pathologies and the specificity of the pediatric population
don’t hold pharma industries nor governments to delin-
eate phase III trials and prove the benefit of such com-
pounds for refractory osteosarcomas.
In 2008, the GSF-GETO established a National Ob-
servatory for The off-label Use Of Targeted Therapies
in Sarcomas (OUTC’S) as a resource for the research
into the use of TTs in routine practice. All medical data
regarding the use of off-label TTs in sarcomas was col-
lected in a prospective way to analyze activity and tox-
icity of TTs in these tumors [13]. This report aims to
describe the utilization, efficacy, and safety data on
osteosarcoma patients registered in OUTC’S in order to
identify TTs which warrant further investigations in
this pathology.
Methods
Patients/Registry
Patients who met the following criteria were included:
osteosarcoma upon histological diagnosis, no age-limit,
not amenable to curative treatment or inclusion in
clinical trial, treatment in France. They received an in-
formation letter. Oral consent for data collection and
use for research purpose was requested before inclusion.
Children could be included with parents’ oral consent.
As reported previously, all details of the methodology
was anticipated. Once a patient registered, he was evalu-
ated by his referring doctor and a follow-up file was sent
every two months to the coordination center.
Competent authorities approval
All data was collected by the coordination center
(Centre Léon Bérard, Lyon) upon approval of the local
Clinical Trial Review Committee (CREC, Lyon, France),
the French Consultative Committee for the Data Pro-
cessing in Health Research (CCTIRS, Paris, France) and
the French data protection authority (National Commis-
sion of Informatics and Liberty, Paris, France, declaration
n°1375805). Most decisions of treatment involving off-
label TT treatment were made during a Multidisciplinary
Tumor Board (MTB), as defined by the French Sarcoma
Network (NetSarc) [14].
Data collection and study endpoints
The primary objective was to describe the efficacy of off-
label TTs in osteosarcoma patients. Endpoints were
response rate for each TT: rate of complete and partial
remission (CR, PR) according to RECIST (Response
Evaluation Criteria for Solid Tumors [15]), disease con-
trol rate (rate of CR, PR and stable disease as best re-
sponse), Progression-Free-Survival (PFS), Overall
Survival (OS) and duration of response. The secondary
objective was the characterization of toxicities.
Statistical methods
PFS was calculated from the beginning of TT to the date
of the event, defined as the first documented progression
or death whatever the cause under treatment. Patients
who did not experience an event were censored at the
date of treatment discontinuation or at the date of last
contact for patients still under treatment. OS was calcu-
lated from the beginning of treatment until the date of
death whatever the cause, and censored at the date of
last contact for patients alive. PFS and OS were esti-
mated by the Kaplan Meier method with their 95 % con-
fidence interval (CI) and comparisons were done by a
logrank test, in the XLstat software. Safety evaluation
was based on the frequency and severity of toxicities
graded according to the Common Terminology Criteria
for Adverse Events [16].
Patients could be included in the Observatory for each
consecutive line of TT. All analyses were performed on
the total number of treatment lines, except for data
regarding OS which was analyzed on the total number
of patients included at least once in the study. Regarding
patients included several times, OS was defined as the
time between the first inclusion and date of the last
follow up for the last treatment. The database was
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locked for statistical analysis in July 2013. This is a de-
scriptive analysis.
Results
Patient characteristics
From September 2009 to July 2013, 29 patients from 12
centers (8 pediatric, 1 adult and 3 mixed) were registered
and received 33 lines of TTs. Median age at the beginning
of TTs was 19 (range 9 to 72) and median duration be-
tween the diagnosis of osteosarcoma and the beginning of
a TTs was 2.7 years (range 7 months to 7 years). A median
of 3 lines of chemotherapy (range 1–8) was administrated
before starting TTs (Table 1).
Off-label targeted therapies
The decision of using off-label TTs was made in a MTB
for 24 patients (73 %). There was no difference in the
decision process between adults and pediatric units.
Sirolimus was used for 23 patients (70 %), mostly in
combination with chemotherapy (n = 20). Multi-targeted
Tyrosine Kinase Inhibitors (TKI) were used in 10 pa-
tients (Table 2). Doses and modalities of treatment were
heterogeneous.
Efficacy of targeted therapies
Response to treatment
Stabilization of the disease was observed in 15 patients
(45.5 %, 95 % CI [28.5–62.4]), with a median duration of
stabilization of 4.8 months (range 1 to 17).
Among the 20 patients in progressive disease treated with
sirolimus, 7 (35 %) were stabilized: 1 with sirolimus alone, 6
in combination. Two patients treated in CR were main-
tained 4.8, 12.9 months respectively. The third patient
stopped treatment after 17 months of continuing CR.
Under sorafenib (n = 4), stabilization was observed for
3 patients. One clinical PR (not RECIST) and one
stabilization were observed under sunitinib. The patient
treated with pazopanib had rapid disease progression
(Table 2).
Follow up and survival
The median follow-up time after diagnosis was 3 years
(range 1.1 to 7.2). The median PFS for the whole group
was 2.3 months (95 % CI [1.9–3.7]). The PFS was 61 %
at 2 months (n = 20), 30 % at four months (n = 10), 15 %
at six months (n = 5) (Fig. 1).
The median PFS was 3 months (95 % CI [2.2–5.4]) for
patients treated by sirolimus (2.7 months in combination,
5.7 months alone) and 1.8 months (95 % CI [1.3–2.8]) for
patients receiving TKI (Fig. 2). Six-month PFS was 22 %
for patients receiving sirolimus, and 0 % for other TTs. In
a multivariate analysis, the only factor significantly affect-
ing the prognosis was the TT used: patients treated by
sirolimus had a better PFS, with a hazard ratio of 2.7
(95 % CI [1.05–7.1]) (Table 3).
The median PFS was 2 months (95 % CI [0.8–9]) for 4
patients treated at first relapse, 2.3 months (95 % CI
[1.9–6.9]) for 12 patients experiencing a second relapse,
Table 1 Population characteristics
Gender
Male 19 66 %
Female 10 33 %
Age at diagnosis
18,1
median (min-max) 19 8 – 65
Age at initiation of
treatment
19
median (min-max) 20 9 – 72
≤18 years 15 45 %
Histological subtype of
osteosarcoma
osteoblastic 18 62 %
chondroblastic 5 17 %
osteogenic 3 10 %
telangiectasic 2 7 %
pleiomorphic 1 4 %
Tumor grade
Grade III 29 100 %
Stage at beginning of
TT
progression 30 91 %
complete remission
after relapse
3 9 %
Localization of relapse
localized 0 0 %
metastatic 24 73 %
both 9 27 %
Number of previous
treatment lines
2,9
median (min-max) 3 1 – 8
0 0 0 %
1 4 12 %
2 12 36 %
3 10 30 %
≥4 7 21 %
Delay diagnosis -
initiation of TT
2,8 years
median (min-max) 2,7 years (0,6 – 7 years)
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3 months (95 % CI [1.3–4.7]) for 10 patients at third re-
lapse, and 2.2 months (95 % CI [1.8–3.5]) for 7 patients
at fourth (or more) relapse.
Five patients achieving 6-months PFS had received the
combination sirolimus-cyclophosphamide. Their median
age was 17 at the beginning of TTs. One patient experi-
enced a first relapse while the others had a second, and
two were in complete remission at the treatment
initiation.
The median OS was 6.8 months (95 % CI [4.7–12.1]).
OS at one year was 24 % (30 % with sirolimus, 10 % with
TKI).
Tolerance of treatment
Treatment interruption occurred in 26 cases (79 %) due to
disease progression and in 3 cases (9 %) due to death
caused by cancer. Only one TT line was stopped for toxic-
ities (grade 3 hematuric cystitis due to cyclophosphamide).
Among 33 lines of treatment, 22 (67 %) patients reported
at least one adverse event (AE). Thirty-nine AEs were re-
ported. Gastro-intestinal toxicity was observed in 27 % of
patients (nausea, vomiting, stomatitis), hematologic toxicity
in 24 % and fatigue in 24 %. Other AEs (skin, infection,
headache, alopecia, depression) were reported in less than
10 % of cases (Table 4).
Table 2 Duration of response
Targeted
Therapy
N = 33 Stable disease as
best response
Median duration of
response (months)
Sirolimus
alone
3 1 4,75
Sirolimus Cy 13 7 (3 maintained
complete
remission)
5,4
Sirolimus Cy
Adriamycine
1 1 6,2
Sirolimus Cy
Vinorelbine
3 0
Sirolimus Cy
Zolendronate
1 1 9
Sirolimus
Irinotecan
2 0
Sorafenib 4 3 3,1
Sunitinib 5 2 (1 PR) 3,4
Pazopanib 1 0
Total 33 15 4,8
Cy cyclophosphamide
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 5 10 15 20 25 30
months
Overal and progression-free survival
PFS OS
6,8 months
2,3 months
Fig. 1 Overall survival and progression free survival
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Most of AEs were grade 1–2 (72 % of AEs). Hematologic,
fatigue, and skin, grade 3, were observed for 9 patients
(27 %). Grade 4 was hematologic and affected only 2
patients treated by sirolimus – cyclophosphamide –
vinorelbine or adriamycine. The median grade of toxic-
ities with TKI was 2.3, and with sirolimus 1.7.
Five TTs (15 %) were modified for toxicity (dose re-
duction or temporary interruption). No toxic death was
reported.
Discussion
This study reported a 45.5 % disease control rate with
TTs used off-label in refractory relapsed osteosarcomas
with a good tolerance profile. In a multivariate analysis,
PFS seemed superior for patients receiving sirolimus
compared to other TTs.
Many molecular abnormalities are identified in osteo-
sarcomas giving the cancer cells some particular charac-
teristics: proliferative signals (PDGFR, IGFR, c-KIT),
resistance to retroaction signals (p53, RB), resistance to
cell death (ERK, Bcl-2), angiogenesis (VEGFR, PDGFR),
resistance to immune destruction (IFN) [12]. Potential
TTs could either inhibit growth factor signaling path-
ways, or enhance apoptosis, or inhibit the metastatic
process, or modulate the antitumor immune response,
or modulate the bone microenvironment to increase
local control of the primary tumor, limit metastatic
spread, and finally improve patient survival [17].
mTOR is an intracellular protein, playing a major role
in protein synthesis and influencing the cell growth, dif-
ferentiation and apoptosis: this pathway is unregulated
in many cancers, leading to the permanent activation,
often under the influence of IGF1R. mTOR also plays a
role in angiogenesis by controlling the production of
HIF (Hypoxia Inducible Factor) [18]. Preclinical studies
demonstrated that sirolimus, the main mTOR inhibitor,
blocks the ezrin pathway implicated in the metastatic
migration of osteosarcomas [19]. In 2012, a phase II
study reported a clinical benefit in 28.8 % of patients
treated with ridaforolimus for a metastatic or inoperable
sarcoma with an increased PFS compared to untreated
patients [20]. Another phase II study testing the associ-
ation of sirolimus and cyclophosphamide in soft tissue
and bone sarcomas, highlighted a synergic effect of the
two drugs, leading to an increased PFS with a good tol-
erance [21]. A double blind phase III maintenance trial
comparing ridaforolimus and placebo in advanced sar-
coma after stabilization or response with chemotherapy,
enrolled 50 bone sarcoma patients showing a longer PFS
and a 28 % reduction in the risk of death or progression
with the maintenance strategy [22]. This data constituted
the rational for using mTor inhibitors in refractory
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10 12 14 16 18
months
Progression-free survival
Sirolimus other targeted therapies
1,8 months
3 months
HR 2,73 (95%CI [1,05-7,1])
p=0,009
Fig. 2 Progression-free survival according to treatment
Table 3 Multivariate analysis: factors influencing PFS
Hazard Ratio 95 % CI p
Delay before treatment 1,00 0,99–1 0,44
≤2 previous treatment lines 0,69 0,27 – 1,74 0,43
Histology : osteoblastic 0,80 0,37 – 1,73 0,57
Treatment by Sirolimus 2,73 1,05 – 7,1 0,04
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osteosarcomas, first in adults and recently in pediatric
population (Table 5). Data provided by OUTC’S registry
confirmed the value of this agent in osteosarcomas espe-
cially combined with conventional chemotherapy to pro-
long survival and time to progression in this particularly
dismal prognosis group.
Sorafenib inhibits B-raf, c-KIT, PDGFR, VEGFR and
RET. In osteosarcoma, sorafenib inhibits the proliferation
of tumor, angiogenesis (VEGF), invasion (MMP2), the
emergence of pulmonary metastases (Erzin/β4-integrin/
PI3K) and induces apoptosis [23]. This drug has already
been approved for renal and hepatocarcinoma treatment
and has shown good responses in angiosarcomas [24].
Yet, the use of sorafenib in osteosarcomas is mainly based
on a phase II study, conducted in 35 patients with pro-
gression despite standard treatment and reporting 5 PRs,
a clinical benefit rate of 29 % and a four-month PFS of
46 % [25].
Sunitinib inhibits FLT3, c-KIT, PDGFR and VEGF.
Efficacy was observed with in vivo models, mostly
pediatric tumors, including Ewing sarcoma xenografts
[26]. Clinical benefit is reported for 4 patients with
sarcomas in phase I [27] and 34 in phase II studies [28].
Pazopanib is mainly steered against VEGFR and
PDGFR. A phase II study reported 9 cases of PR and
improvement of OS and PFS for 143 patients with pro-
gressive soft tissue sarcoma [29]. A randomized double
blind phase III study of pazopanib versus placebo,
showed improved OS and PFS for a metastatic soft
tissue sarcoma after failure of chemotherapy treatment
[30]. A randomized double-blinded phase II is currently
open to evaluate regorafenib, a promising TKI [31] in
advanced bone sarcomas [32]. Based on this literature,
TKI have been used off-label in adult refractory sar-
coma first, thereafter by pediatricians influenced by
adult practices despite the paucity of pharmacological
data in pediatric population.
We report in this study only one objective response
after initiation of TT. It has been suggested that the
evaluation of TTs efficacy could not be done by RECIST
compared to conventional treatments because TKI are
mainly cytostatic. Some cases of cystic tumors after
treatment by TKI have been reported [33]. Indeed, a
stable disease induced by a TT could be considered as a
satisfying response and a significant clinical benefit given
the poor prognosis of metastatic refractory sarcomas.
In order to guide the objectives of clinical trials, the
EORTC Sarcoma Group (European Organization for
Research and Treatment of Cancer) defined that a
second-line treatment could be considered active if it
showed a 6-month PFS of 40 % and as inactive if it was
below 20 % [33]. In our study, six-month PFS was 15 %
(22 % with sirolimus, 0 % with TKI), but all patients in-
cluded had very poor prognosis factors: inoperable
tumor, high grade histology, treatment-line failures.
Most published series about this population reported
dismal prognosis, with short median survival especially
after several relapses [11, 34]. In this cohort, the one-
year OS of 24 % and median survival of 6.8 months
could be a significant result. The difference observed in
median PFS between sirolimus group and TKI group
(2.3 versus 1.8 months) encourages investigating this
drug in a clinical trial.
Given the number of different mechanisms involved in
carcinogenesis and treatment failures, a molecular study
of each tumor could guide the indications of TTs and
compounds. Some mechanisms lead to the cell resist-
ance to Sirolimus, in particular because only the com-
plex MTORC1 is sensitive to Sirolimus, whereas
MTORC2 is resistant [17]. The activation of MTORC2
leads to treatment failure. This mechanism can be
blocked by the association with Sorafenib: in vitro and
Table 4 Adverse events
Total Grade
N(%) 1 2 3 – 4
Sirolimus (n = 23)
At least 1 toxicity reported 14 (60)
Intestinal toxicity 8 (34) 7 1
Skin toxicity, infections 1 (4) 1 1
Hematologic toxicity 6 (26) 1 1 4
Urinary toxicity 1 (4) 1
Neurological toxicity 3 (13) 2 1
Other (fatigue, pain) 6 (26) 4 2
Dose modification 2 (9)
Discontinuation for toxicity 1 (4)
Sunitinib (n = 5)
At least 1 toxicity reported 4 (80)
Hematologic toxicity 2 (40) 2
Pulmonary toxicity 1 (20) 1
Other (fatigue) 2 (40) 2 1
Dose modification 1 (20)
Sorafenib (n = 4)
At least 1 toxicity reported 3 (75)
Skin toxicity, infections 2 (50) 1 1
other (fatigue, psychological) 4 (100) 1 2
Dose modification 2 (50)
Pazopanib (n = 1)
At least 1 toxicity reported 1
Intestinal toxicity 1 1
Other (fatigue) 1 1
Dose modification 0
Total ≥1 AE: 22 17 11 11
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in vivo, the combination of the two drugs increases the
anti-tumor, anti-angiogenic and anti-metastatic activity
[35]. Despite this data, no combination of TKI with
mTOR inhibitor was reported in OUTC’S: it could be
worth exploring this strategy.
In this study, tumor control lasted more than 6 months
for 5 patients. These patients had a median age of 17 at
the TT initiation, which is below the median age of the
whole group and compatible with data showing a better
response to chemotherapy in children [36]. All these
patients received sirolimus in association with cyclo-
phosphamide. One patient was treated at first relapse
and the others at second relapse, suggesting that effi-
ciency of sirolimus could be optimized when used with
minimal tumoral disease.
We must underscore that three patients received a main-
tenance treatment combining sirolimus-cyclophosphamide,
after complete remission by surgery and chemotherapy.
This strategy is developing in sarcomas, supported by stud-
ies suggesting that it could improve survival and decrease
the risk of relapse in high-risk patients [22, 37] and must be
confirmed in randomized clinical trial dedicated to main-
tenance therapy including PFS, OS and quality of life.
Observed data of toxicity are similar to what was
already described in clinical trials [13]. No major toxic
effect has been reported and only one patient had to
stop TTs because of toxicity, showing that tolerance to
TTs is acceptable, even in children.
The main limitation of this study is the small number
of patients, due to the rarity of these tumors, which can
reduce the statistical power, in particular for the
comparison between TKI and sirolimus (since the CI of
the hazard ratio approximates 1). The specificities of
pediatric population make it difficult to launch clinical
trials assessing efficacy of TTs in osteosarcomas. Regis-
tering patient in a national database like OUTC’S is an
opportunity to obtain more information about safety
and efficacy of drugs used off-label with a rational based
on published data.
Conclusion
Targeted therapies could play a part in the treatment of
refractory osteosarcomas or in maintenance for patients
with a high risk of relapse. Tolerance is acceptable, even
for patients under 18. This data suggests that sirolimus
could have an interesting anti-tumor activity in osteosar-
comas and deserves to be evaluated in a prospective
trial, either alone or in combination with chemotherapy.
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